These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 28634748)

  • 21. Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study.
    Yamaguchi K; Fujitani K; Nagashima F; Omuro Y; Machida N; Nishina T; Koue T; Tsujimoto M; Maeda K; Satoh T
    Gastric Cancer; 2018 Nov; 21(6):1041-1049. PubMed ID: 29508095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).
    Jung M; Ryu MH; Oh DY; Kang M; Zang DY; Hwang IG; Lee KW; Kim KH; Shim BY; Song EK; Sym SJ; Han HS; Park YL; Kim JS; Lee HW; Lee MH; Koo DH; Song HS; Lee N; Yang SH; Choi DR; Hong YS; Lee KE; Maeng CH; Baek JH; Kim S; Kim YH; Rha SY; Cho JY; Kang YK
    Gastric Cancer; 2018 Sep; 21(5):819-830. PubMed ID: 29427038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
    Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
    Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.
    Smit EF; Garon EB; Reck M; Cappuzzo F; Bidoli P; Cohen RB; Gao L; O'Brien LM; Lee P; Zimmermann A; Ferry DR; Melemed AS; Pérol M
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):77-86. PubMed ID: 29721850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.
    Van Cutsem E; Muro K; Cunningham D; Bodoky G; Sobrero A; Cascinu S; Ajani J; Oh SC; Al-Batran SE; Wainberg ZA; Wijayawardana SR; Melemed S; Ferry D; Hozak RR; Ohtsu A;
    Eur J Cancer; 2020 Mar; 127():150-157. PubMed ID: 32014812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas.
    Ueda S; Satoh T; Gotoh M; Gao L; Doi T
    Oncologist; 2015 May; 20(5):493-4. PubMed ID: 25888272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
    Fuchs CS; Tomasek J; Yong CJ; Dumitru F; Passalacqua R; Goswami C; Safran H; Dos Santos LV; Aprile G; Ferry DR; Melichar B; Tehfe M; Topuzov E; Zalcberg JR; Chau I; Campbell W; Sivanandan C; Pikiel J; Koshiji M; Hsu Y; Liepa AM; Gao L; Schwartz JD; Tabernero J;
    Lancet; 2014 Jan; 383(9911):31-39. PubMed ID: 24094768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review.
    Zhang X; Zhou L; Zhou C; Shen L
    Adv Ther; 2024 Jun; 41(6):2112-2132. PubMed ID: 38619719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices.
    Paulson AS; Hess LM; Liepa AM; Cui ZL; Aguilar KM; Clark J; Schelman W
    Gastric Cancer; 2018 Sep; 21(5):831-844. PubMed ID: 29397460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the safety of ramucirumab in Japanese patients with advanced gastric cancer.
    Iwai M; Ito D; Asano H; Adachi S; Okada K; Kimura M; Usami E; Matsuo K; Yoshimura T; Teramachi H
    Pharmazie; 2018 May; 73(5):309-312. PubMed ID: 29724300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial.
    Yamaguchi K; Shimada Y; Hironaka S; Sugimoto N; Komatsu Y; Nishina T; Omuro Y; Tamura T; Piao Y; Homma G; Jen MH; Liepa AM; Muro K
    Clin Drug Investig; 2021 Jan; 41(1):53-64. PubMed ID: 33355909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer.
    Chung HC; Kok VC; Cheng R; Hsu Y; Orlando M; Fuchs C; Cho JY
    Asia Pac J Clin Oncol; 2018 Jun; 14(3):204-209. PubMed ID: 29318751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer.
    Khan U; Shah MA
    Expert Opin Biol Ther; 2019 Nov; 19(11):1135-1141. PubMed ID: 31452409
    [No Abstract]   [Full Text] [Related]  

  • 34. East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL).
    Park K; Kim JH; Cho EK; Kang JH; Shih JY; Zimmermann AH; Lee P; Alexandris E; Puri T; Orlando M
    Cancer Res Treat; 2016 Oct; 48(4):1177-1186. PubMed ID: 26910471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer.
    Cascinu S; Bodoky G; Muro K; Van Cutsem E; Oh SC; Folprecht G; Ananda S; Girotto G; Wainberg ZA; Miron MLL; Ajani J; Wei R; Liepa AM; Carlesi R; Emig M; Ohtsu A
    Oncologist; 2021 Mar; 26(3):e414-e424. PubMed ID: 33274542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma.
    Murahashi S; Takahari D; Wakatsuki T; Fukuda N; Ichimura T; Ogura M; Ozaka M; Shinozaki E; Nakayama I; Matsushima T; Osumi H; Chin K; Yamaguchi K
    Int J Clin Oncol; 2018 Feb; 23(1):92-97. PubMed ID: 28913565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Fuchs CS; Shitara K; Di Bartolomeo M; Lonardi S; Al-Batran SE; Van Cutsem E; Ilson DH; Alsina M; Chau I; Lacy J; Ducreux M; Mendez GA; Alavez AM; Takahari D; Mansoor W; Enzinger PC; Gorbounova V; Wainberg ZA; Hegewisch-Becker S; Ferry D; Lin J; Carlesi R; Das M; Shah MA;
    Lancet Oncol; 2019 Mar; 20(3):420-435. PubMed ID: 30718072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy.
    Roviello G; Martina C; Winchler C; De Gennaro Aquino I; Papa F; Buttitta E; Rossi G; Antonuzzo L
    J Gastrointest Cancer; 2023 Sep; 54(3):802-808. PubMed ID: 36109437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Ramucirumab - a new anticancer agent].
    Telekes A; Deme D
    Orv Hetil; 2016 Oct; 157(40):1587-1594. PubMed ID: 27690622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma.
    Moy RH; Greally M; Chou JF; Li J; Desai AM; Chalasani SB; Won E; Kelsen DP; Ilson DH; Janjigian YY; Capanu M; Ku GY
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):255-265. PubMed ID: 35066693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.